Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9

Glaucoma is a common cause of blindness, yet current therapeutic options are imperfect. Clinical trials have invariably shown that reduction in intraocular pressure (IOP) regardless of disease subtype prevents visual loss. Reducing ciliary body aqueous humor production can lower IOP, and the adeno-a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Ther
Autori principali: Wu, Jiahui, Bell, Oliver H., Copland, David A., Young, Alison, Pooley, John R., Maswood, Ryea, Evans, Rachel S., Khaw, Peng Tee, Ali, Robin R., Dick, Andrew D., Chu, Colin J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Gene & Cell Therapy 2020
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7054720/
https://ncbi.nlm.nih.gov/pubmed/31981492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2019.12.012
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi